Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis.
Journal
American journal of hematology
ISSN: 1096-8652
Titre abrégé: Am J Hematol
Pays: United States
ID NLM: 7610369
Informations de publication
Date de publication:
01 01 2022
01 01 2022
Historique:
revised:
09
10
2021
received:
08
09
2021
accepted:
14
10
2021
pubmed:
27
10
2021
medline:
15
2
2022
entrez:
26
10
2021
Statut:
ppublish
Résumé
Monoclonal B-cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL) are clonal B-cell disorders associated with an increased risk of infections and impaired vaccination responses. We investigated the immunogenicity of recombinant zoster vaccine (RZV) in these patients. Individuals with MBL/untreated CLL and Bruton tyrosine kinase inhibitor (BTKi)-treated CLL patients were given two doses of RZV separated by 2 months. Responses assessed at 3 and 12 months from the first dose of RZV by an anti-glycoprotein E ELISA antibody assay and by dual-color Interferon-γ and Interleukin-2FLUOROSPOT assays were compared to historic controls matched by age and sex. About 62 patients (37 MBL/untreated CLL and 25 BTKi-treated CLL) were enrolled with a median age of 68 years at vaccination. An antibody response at 3 months was seen in 45% of participants, which was significantly lower compared to historic controls (63%, p = .03). The antibody response did not significantly differ between MBL/untreated CLL and BTKi-treated CLL (51% vs. 36%, respectively, p = .23). The CD4+ T-cell response to vaccination was significantly lower in study participants compared to controls (54% vs. 96%, p < .001), mainly due to lower responses among BTKi-treated patients compared to untreated MBL/CLL (32% vs. 73%, p = .008). Overall, only 29% of participants achieved combined antibody and cellular responses to RZV. Among participants with response assessment at 12 months (n = 47), 24% had antibody titers below the response threshold. Hypogammaglobulinemia and BTKi therapy were associated with reduced T-cell responses in a univariate analysis. Strategies to improve vaccine response to RZV among MBL/CLL patients are needed.
Identifiants
pubmed: 34699616
doi: 10.1002/ajh.26388
pmc: PMC9199015
mid: NIHMS1750976
doi:
Substances chimiques
Herpes Zoster Vaccine
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
90-98Subventions
Organisme : NCI NIH HHS
ID : P30 CA015083
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI149746
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA197120
Pays : United States
Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Lancet. 2010 Oct 2;376(9747):1164-74
pubmed: 20888994
J Clin Invest. 2018 Oct 1;128(10):4429-4440
pubmed: 30024861
J Virol. 2019 Jul 17;93(15):
pubmed: 31092579
Leukemia. 2020 Aug;34(8):2012-2024
pubmed: 32457353
Leukemia. 1995 Nov;9(11):1902-9
pubmed: 7475282
J Clin Invest. 2008 Jul;118(7):2427-37
pubmed: 18551193
N Engl J Med. 2016 Sep 15;375(11):1019-32
pubmed: 27626517
N Engl J Med. 2014 Aug 14;371(7):635-45
pubmed: 25119609
Clin Adv Hematol Oncol. 2014 Jul;12(7):440-50
pubmed: 25322324
Blood. 2012 Aug 16;120(7):1412-21
pubmed: 22547582
Blood. 2013 Feb 28;121(9):1612-21
pubmed: 23247726
Clin Cancer Res. 2012 Mar 1;18(5):1426-34
pubmed: 22241792
MMWR Morb Mortal Wkly Rep. 2018 Jan 26;67(3):103-108
pubmed: 29370152
MMWR Recomm Rep. 2008 Jun 6;57(RR-5):1-30; quiz CE2-4
pubmed: 18528318
Clin Cancer Res. 2018 Sep 15;24(18):4371-4379
pubmed: 29895707
Leukemia. 2013 Jan;27(1):136-41
pubmed: 22781591
Leukemia. 2021 Jan;35(1):239-244
pubmed: 32203143
Lancet Respir Med. 2017 Sep;5(9):738-746
pubmed: 28736045
N Engl J Med. 2021 Aug 12;385(7):661-662
pubmed: 34161700
Blood. 2018 Jun 21;131(25):2745-2760
pubmed: 29540348
Vaccine. 2021 Feb 12;39(7):1122-1130
pubmed: 33461835
Lancet Infect Dis. 2019 Sep;19(9):988-1000
pubmed: 31399377
Blood. 2021 Jan 14;137(2):185-189
pubmed: 33259596
J Gen Intern Med. 2005 Aug;20(8):748-53
pubmed: 16050886
Leukemia. 2010 Mar;24(3):512-20
pubmed: 20090778
Leukemia. 2021 Jun;35(6):1788-1791
pubmed: 33128020
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
J Clin Invest. 2017 Aug 1;127(8):3052-3064
pubmed: 28714866
Front Immunol. 2021 Jan 20;11:612244
pubmed: 33552073
J Infect Dis. 2015 Apr 15;211(8):1279-87
pubmed: 25371534
Leuk Lymphoma. 2017 Aug;58(8):1973-1976
pubmed: 27960571
J Immunol. 2017 Feb 15;198(4):1740-1747
pubmed: 28077600
JAMA. 2019 Jul 9;322(2):123-133
pubmed: 31287523
J Virol. 2021 May 24;95(12):
pubmed: 33762414
Cancer. 2019 Apr 15;125(8):1301-1312
pubmed: 30707761
Blood. 2014 Nov 6;124(19):2921-9
pubmed: 25237196
Cancer. 2008 Jul 15;113(2):383-7
pubmed: 18470901
Clin Infect Dis. 2020 Jan 2;70(2):181-190
pubmed: 30843046
Blood. 2008 Aug 15;112(4):975-80
pubmed: 18411418
Blood. 2021 Jun 10;137(23):3165-3173
pubmed: 33861303
Blood Rev. 2018 Sep;32(5):387-399
pubmed: 29571669
J Infect Dis. 2018 May 5;217(11):1750-1760
pubmed: 29529222
Blood. 2013 Oct 10;122(15):2539-49
pubmed: 23886836
Semin Oncol. 2006 Apr;33(2):240-9
pubmed: 16616071